OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Schmid on Activity With Neoadjuvant Pembrolizumab in TNBC

January 21st 2020

Peter Schmid, MD, PhD, discusses the benefit of pembrolizumab when added to neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Dr. Pagel on the ELEVATE-TN Trial in CLL

January 21st 2020

John M. Pagel, MD, PhD, discusses the phase III ELEVATE-TN trial in chronic lymphocytic leukemia.

Dr. Wang on the ZUMA-2 Trial in Relapsed/Refractory MCL

January 21st 2020

Michael Wang, MD, discusses the results of the phase II ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Incorporating Precision Medicine into Oncology

January 21st 2020

Terrill Jordan, LLM, JD, MAcc, discusses challenges regarding the utility of precision medicine in oncology.

Dr. Dunavin on Frontline Treatment in Myelofibrosis

January 21st 2020

Neil Dunavin, MD, MS, discusses frontline treatment in myelofibrosis.

Dr. Moskowitz on Important Updates in Hodgkin Lymphoma

January 21st 2020

Alison J. Moskowitz, MD, discusses important updates in Hodgkin lymphoma.

Dr. Mohler on Need for Genetic Counselors for Early Detection of Prostate Cancer

January 20th 2020

James L. Mohler, MD, discusses the need for genetic counselors in the detection and treatment of prostate cancer.

Dr. Copeland on the Role of Chemotherapy in Ovarian Cancer

January 18th 2020

Larry J. Copeland, MD, discusses the role of chemotherapy in ovarian cancer.

Dr. Kaplan on Frontline Treatment Options in Follicular Lymphoma

January 18th 2020

Lawrence D. Kaplan, MD, discusses frontline treatment options in follicular lymphoma.

Dr. Wong on Mitigating Toxicities of Selinexor in R/R Multiple Myeloma

January 18th 2020

Sandy Wong, MD, discusses ways to mitigate the toxicities of selinexor in patients with relapsed/refractory multiple myeloma.

Dr. Hellmann on the Utility of Minimally Invasive Surgery in Cervical Cancer

January 18th 2020

Mira Hellmann, MD, discusses the utility of minimally invasive surgery in cervical cancer.

Utility of Trapelo to Increase Molecular Testing Rates

January 18th 2020

Lori Brisbin, discusses Trapelo, a new automated tool to help increase the number of patients who receive molecular testing as a precision medicine effort.

Dr. Hudson on Repeat Molecular Testing in Relapsed/Refractory NSCLC

January 18th 2020

Kathryn E. Hudson, MD, discusses performing repeat biopsies on patients with relapsed/refractory non–small cell lung cancer.

Dr. Burris on Ongoing Research With ADCs in TNBC

January 18th 2020

Howard A. "Skip" Burris, III, MD, FASCO, FACP, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses ongoing research with antibody-drug conjugates (ADCs) in triple-negative breast cancer.

Dr. Garcia on Research With the Combination of Navitoclax/Ruxolitinib in Myelofibrosis

January 18th 2020

Jacqueline S. Garcia, MD, instructor in Medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses research with the combination of navitoclax and ruxolitinib (Jakafi) in patients with myelofibrosis.

Dr. Ribeiro on Criteria for Determining Borderline Resectability in Pancreatic Cancer

January 18th 2020

Afonso Ribeiro, MD, medical director of Advanced Endoscopy and Gastroenterology at Memorial Healthcare System, discusses the criteria that can be used to determine whether a patient with pancreatic cancer is borderline resectable.

Dr. Yorio on Searching for Biomarkers in Metastatic Lung Cancer

January 18th 2020

Jeff Yorio, MD, discusses the search for biomarkers and using next-generation sequencing in metastatic lung cancer.

Dr. Munshi on the Antitumor Effect of NKTR-255 in Patients With Myeloma

January 17th 2020

Nikhil C. Munshi, MD, discusses the antitumor effect of NKTR-255 in patients with multiple myeloma.

Dr. Bryce on Next-Generation Radiopharmaceuticals in Prostate Cancer

January 17th 2020

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the use of next-generation radiopharmaceuticals in prostate cancer.

Dr. Hurvitz on the Evolution of Treatment in Metastatic HER2+ Breast Cancer

January 17th 2020

Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the evolution of treatment in metastatic HER2-positive breast cancer.